July 2024 in “Actas Dermo-Sifiliográficas” Finasteride and dutasteride do not significantly change beard thickness in men.
April 2024 in “The Journal of urology/The journal of urology” 5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.
March 2024 in “Cleveland Clinic journal of medicine” Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.
November 2023 in “Expert Opinion on Pharmacotherapy” Finasteride and dutasteride are effective in treating male hair loss but can cause sexual side effects and birth defects.
July 2023 in “Dermatology and Therapy” 5-Alpha Reductase Inhibitors are effective for male hair loss and some skin conditions, but their effectiveness in women and safety concerns require careful use.
Canadian lawsuits involving 5-alpha-reductase inhibitors are related to persistent erectile dysfunction side effects, with no judgments against companies yet.
April 2019 in “The Journal of urology/The journal of urology” Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
October 2008 in “The Journal of Urology” Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.
September 2025 in “Journal of Natural Remedies” Herbal drugs show promise for treating alopecia with fewer side effects, but standardization is challenging.
September 2024 in “Frontiers in Neuroendocrinology” 5-alpha reductase inhibitors may help protect the brain and gut in Parkinson's disease.
July 2024 in “Age and Ageing” Men taking dutasteride may have a higher risk of age-related macular degeneration.
January 2021 in “Journal of the European Academy of Dermatology and Venereology” PrEP doesn't increase STI risk in high-risk men, anti-androgen drugs may lower ICU admission for male COVID-19 patients, a 3-point injection is better for crow's feet, and the 'Geriatric-8' tool could help assess frailty in older skin cancer patients.
April 2017 in “The Journal of urology/The journal of urology” 5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
January 2016 in “Archivio italiano di urologia, andrologia” The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.
5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.
March 2014 in “The Journal of Urology” Long-term treatment with finasteride or combined therapy worsens sexual function in men with urinary issues.
November 2011 in “Nature Clinical Practice Urology” 5ARIs effectively treat and manage BPH by reducing prostate size and symptoms.
January 2023 in “The Egyptian Journal of Hospital Medicine” Dutasteride is effective for treating hair loss.
April 2016 in “The Journal of Sexual Medicine” Younger people (median age 35) experience more PFS-like symptoms with 1mg finasteride; more research needed.
January 2020 in “The Journal of Sexual Medicine” Using 5α-reductase inhibitors for hair loss can cause lasting sexual, physical, mental, and vascular health issues in men, even after stopping the medication.
May 2017 in “Urology and andrology” Finasteride and dutasteride, used for prostate issues and hair loss, can cause side effects like sexual dysfunction and mental issues, which may continue even after stopping the medication, a condition called post-finasteride syndrome, for which there's currently no cure.
July 2018 in “Reactions Weekly” Lower finasteride doses had more side effects; dutasteride caused back pain; more research needed on post-finasteride syndrome.
97 citations
,
April 2016 in “Andrology” Hormones and metabolism play a complex role in prostate enlargement, and more research is needed to improve diagnosis and treatment.
63 citations
,
December 2013 in “PLoS ONE” Finasteride may reduce prostate cancer spread by lowering certain enzyme levels.
54 citations
,
October 2019 in “Cochrane library” Some drugs may reduce prostatitis symptoms short-term with few side effects.
38 citations
,
January 2019 in “International Journal of Women's Dermatology” The document concluded that more research is needed to find the best treatment for Frontal fibrosing alopecia.
21 citations
,
May 2021 in “Prostate Cancer and Prostatic Diseases” COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.
5 citations
,
December 2024 in “Archivio Italiano di Urologia e Andrologia” Personalized treatment is crucial for effectively managing benign prostatic hyperplasia (BPH).
4 citations
,
February 2016 in “The Journal of urology/The journal of urology” Most care for benign prostatic hyperplasia follows guidelines, but 5-α reductase inhibitors are often used incorrectly.
4 citations
,
August 2011 in “The Lancet Oncology” Off-label drug use can be risky and requires careful consideration to ensure patient safety.